title: Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations.
abstract: Supraventricular tachyarrhythmias are reported in up to 40% of patients early after coronary artery bypass graft operations. In a randomized study, we compared the efficacy and safety of the class III antiarrhythmic beta-blocking drug sotalol versus propranolol at low and high doses in the prevention of supraventricular tachyarrhythmias in 429 consecutive patients after coronary artery bypass graft operations. Patients with severely depressed left ventricular function and other contraindications for beta-blockers were excluded. From the fourth hour up to the sixth day after coronary artery bypass, 74 patients received low-dose sotalol (40 mg every 8 hours), 66 patients low-dose propranolol (10 mg every 6 hours), 133 patients high-dose sotalol (80 mg every 8 hours), and 156 patients high-dose propranolol (20 mg every 6 hours). Baseline characteristics were comparable in all groups. Supraventricular tachyarrhythmia was observed in 10 of 72 (13.9%) who received low-dose sotalol, 12 of 64 (18.8%) who received low-dose propranolol, 13 of 119 (10.9%) who received high-dose sotalol, and 19 of 139 (13.7%) who received high-dose propranolol (not significant). Drug-related adverse effects necessitating discontinuation of the drug occurred in four receiving low doses (2.9%) and in 31 receiving high doses (10.7%) (p less than 0.02). In conclusion, no medication was found to be superior, although supraventricular tachyarrhythmias tended to be less prevalent in patients treated with sotalol than in those treated with propranolol. Moreover, significantly fewer adverse effects were noted in both low-dose groups. Therefore, low-dose beta-blocking treatment, especially low-dose sotalol, seems preferable.
authors: Department of Cardiology, St Antonius Hospital Nieuwegein, The Netherlands.
authors: M J
authors: MJ
authors: Suttorp
authors: J H
authors: JH
authors: Kingma
authors: R M
authors: RM
authors: Tjon Joe Gin
authors: N M
authors: NM
authors: van Hemel
authors: E M
authors: EM
authors: Koomen
authors: J A
authors: JA
authors: Defauw
authors: A J
authors: AJ
authors: Adan
authors: S M
authors: SM
authors: Ernst
mesh_terms: D000284:Administration, Oral; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D013015:Sotalol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013617:Tachycardia, Supraventricular / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D011433:Propranolol; D013015:Sotalol